ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
2,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
3,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
3,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
3,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
3,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
3,5,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
4,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
5,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
5,2,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
6,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
7,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
7,2,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
8,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
8,2,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
9,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
9,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
10,1,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
11,1,Cluster headache,Headaches NEC,Headaches,Nerv,N
11,2,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
12,1,Vulvovaginal candidiasis,Candida infections,Fungal infectious disorders,Infec,N
13,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
13,2,Dental operation,Dental and gingival therapeutic procedures,Head and neck therapeutic procedures,Surg,N
13,3,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
13,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
13,5,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
13,6,Injection site oedema,Injection site reactions,Administration site reactions,Genrl,N
13,7,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
13,8,Laryngeal oedema,"Laryngeal spasm, oedema and obstruction",Upper respiratory tract disorders (excl infections),Resp,N
13,9,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
14,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
14,2,Pregnancy,"Normal pregnancy, labour and delivery","Pregnancy, labour, delivery and postpartum conditions",Preg,N
15,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
16,1,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
17,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
18,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
18,2,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
19,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
19,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
20,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
21,1,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
22,1,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
23,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
24,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
25,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
25,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
25,3,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
26,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
27,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
27,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
28,1,Death,Death and sudden death,Fatal outcomes,Genrl,N
29,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
30,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
31,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
31,2,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
32,1,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
33,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
33,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
34,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
35,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
35,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
35,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
